213 related articles for article (PubMed ID: 24088113)
1. Primaquine failure and cytochrome P-450 2D6 in Plasmodium vivax malaria.
Bennett JW; Pybus BS; Yadava A; Tosh D; Sousa JC; McCarthy WF; Deye G; Melendez V; Ockenhouse CF
N Engl J Med; 2013 Oct; 369(14):1381-2. PubMed ID: 24088113
[No Abstract] [Full Text] [Related]
2. Real time PCR detection of common CYP2D6 genetic variants and its application in a Karen population study.
Puaprasert K; Chu C; Saralamba N; Day NPJ; Nosten F; White NJ; Dondorp AM; Imwong M
Malar J; 2018 Nov; 17(1):427. PubMed ID: 30442143
[TBL] [Abstract][Full Text] [Related]
3. Differential CYP 2D6 metabolism alters primaquine pharmacokinetics.
Potter BM; Xie LH; Vuong C; Zhang J; Zhang P; Duan D; Luong TL; Bandara Herath HM; Dhammika Nanayakkara NP; Tekwani BL; Walker LA; Nolan CK; Sciotti RJ; Zottig VE; Smith PL; Paris RM; Read LT; Li Q; Pybus BS; Sousa JC; Reichard GA; Marcsisin SR
Antimicrob Agents Chemother; 2015 Apr; 59(4):2380-7. PubMed ID: 25645856
[TBL] [Abstract][Full Text] [Related]
4. Enantioselective metabolism of primaquine by human CYP2D6.
Fasinu PS; Tekwani BL; Nanayakkara NP; Avula B; Herath HM; Wang YH; Adelli VR; Elsohly MA; Khan SI; Khan IA; Pybus BS; Marcsisin SR; Reichard GA; McChesney JD; Walker LA
Malar J; 2014 Dec; 13():507. PubMed ID: 25518709
[TBL] [Abstract][Full Text] [Related]
5. Variation in Human Cytochrome P-450 Drug-Metabolism Genes: A Gateway to the Understanding of Plasmodium vivax Relapses.
Silvino AC; Costa GL; Araújo FC; Ascher DB; Pires DE; Fontes CJ; Carvalho LH; Brito CF; Sousa TN
PLoS One; 2016; 11(7):e0160172. PubMed ID: 27467145
[TBL] [Abstract][Full Text] [Related]
6. Tafenoquine treatment of Plasmodium vivax malaria: suggestive evidence that CYP2D6 reduced metabolism is not associated with relapse in the Phase 2b DETECTIVE trial.
St Jean PL; Xue Z; Carter N; Koh GC; Duparc S; Taylor M; Beaumont C; Llanos-Cuentas A; Rueangweerayut R; Krudsood S; Green JA; Rubio JP
Malar J; 2016 Feb; 15():97. PubMed ID: 26888075
[TBL] [Abstract][Full Text] [Related]
7. Single dose primaquine for clearance of Plasmodium falciparum gametocytes in children with uncomplicated malaria in Uganda: a randomised, controlled, double-blind, dose-ranging trial.
Eziefula AC; Bousema T; Yeung S; Kamya M; Owaraganise A; Gabagaya G; Bradley J; Grignard L; Lanke KH; Wanzira H; Mpimbaza A; Nsobya S; White NJ; Webb EL; Staedke SG; Drakeley C
Lancet Infect Dis; 2014 Feb; 14(2):130-9. PubMed ID: 24239324
[TBL] [Abstract][Full Text] [Related]
8. Differential cytochrome P450 2D metabolism alters tafenoquine pharmacokinetics.
Vuong C; Xie LH; Potter BM; Zhang J; Zhang P; Duan D; Nolan CK; Sciotti RJ; Zottig VE; Nanayakkara NP; Tekwani BL; Walker LA; Smith PL; Paris RM; Read LT; Li Q; Pybus BS; Sousa JC; Reichard GA; Smith B; Marcsisin SR
Antimicrob Agents Chemother; 2015 Jul; 59(7):3864-9. PubMed ID: 25870069
[TBL] [Abstract][Full Text] [Related]
9. Primaquine or other 8-aminoquinoline for reducing Plasmodium falciparum transmission.
Graves PM; Gelband H; Garner P
Cochrane Database Syst Rev; 2015 Feb; (2):CD008152. PubMed ID: 25693791
[TBL] [Abstract][Full Text] [Related]
10. Primaquine: the risks and the benefits.
Ashley EA; Recht J; White NJ
Malar J; 2014 Nov; 13():418. PubMed ID: 25363455
[TBL] [Abstract][Full Text] [Related]
11. Global extent of chloroquine-resistant Plasmodium vivax: a systematic review and meta-analysis.
Price RN; von Seidlein L; Valecha N; Nosten F; Baird JK; White NJ
Lancet Infect Dis; 2014 Oct; 14(10):982-91. PubMed ID: 25213732
[TBL] [Abstract][Full Text] [Related]
12. Primaquine or other 8-aminoquinoline for reducing P. falciparum transmission.
Graves PM; Gelband H; Garner P
Cochrane Database Syst Rev; 2014 Jun; (6):CD008152. PubMed ID: 24979199
[TBL] [Abstract][Full Text] [Related]
13. Assessment of the prophylactic activity and pharmacokinetic profile of oral tafenoquine compared to primaquine for inhibition of liver stage malaria infections.
Li Q; O'Neil M; Xie L; Caridha D; Zeng Q; Zhang J; Pybus B; Hickman M; Melendez V
Malar J; 2014 Apr; 13():141. PubMed ID: 24731238
[TBL] [Abstract][Full Text] [Related]
14. Oxidative activity of primaquine metabolites on rat erythrocytes in vitro and in vivo.
Vásquez-Vivar J; Augusto O
Biochem Pharmacol; 1994 Jan; 47(2):309-16. PubMed ID: 8304975
[TBL] [Abstract][Full Text] [Related]
15. Primaquine pharmacology in the context of CYP 2D6 pharmacogenomics: Current state of the art.
Marcsisin SR; Reichard G; Pybus BS
Pharmacol Ther; 2016 May; 161():1-10. PubMed ID: 27016470
[TBL] [Abstract][Full Text] [Related]
16. CYP2D6 activity and the risk of recurrence of Plasmodium vivax malaria in the Brazilian Amazon: a prospective cohort study.
Brasil LW; Rodrigues-Soares F; Santoro AB; Almeida ACG; Kühn A; Ramasawmy R; Lacerda MVG; Monteiro WM; Suarez-Kurtz G
Malar J; 2018 Feb; 17(1):57. PubMed ID: 29390987
[TBL] [Abstract][Full Text] [Related]
17. Global Epidemiology of Plasmodium vivax.
Howes RE; Battle KE; Mendis KN; Smith DL; Cibulskis RE; Baird JK; Hay SI
Am J Trop Med Hyg; 2016 Dec; 95(6 Suppl):15-34. PubMed ID: 27402513
[TBL] [Abstract][Full Text] [Related]
18. Tafenoquine plus chloroquine for the treatment and relapse prevention of Plasmodium vivax malaria (DETECTIVE): a multicentre, double-blind, randomised, phase 2b dose-selection study.
Llanos-Cuentas A; Lacerda MV; Rueangweerayut R; Krudsood S; Gupta SK; Kochar SK; Arthur P; Chuenchom N; Möhrle JJ; Duparc S; Ugwuegbulam C; Kleim JP; Carter N; Green JA; Kellam L
Lancet; 2014 Mar; 383(9922):1049-58. PubMed ID: 24360369
[TBL] [Abstract][Full Text] [Related]
19. Pre-clinical evaluation of CYP 2D6 dependent drug-drug interactions between primaquine and SSRI/SNRI antidepressants.
Jin X; Potter B; Luong TL; Nelson J; Vuong C; Potter C; Xie L; Zhang J; Zhang P; Sousa J; Li Q; Pybus BS; Kreishman-Deitrick M; Hickman M; Smith PL; Paris R; Reichard G; Marcsisin SR
Malar J; 2016 May; 15(1):280. PubMed ID: 27188854
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
